

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. Which of the following drug types best reflects the mechanism of action of nirogacestat?**
 - a. EZH2 inhibitor
 - b. KIT/PDGFR α inhibitor
 - c. Small-molecule gamma secretase inhibitor**
- 2. Analyses from the open-label extension of the Phase III DeFi study evaluating nirogacestat versus placebo for patients with progressing desmoid tumors reported which of the following efficacy findings?**
 - a. Most patients discontinued nirogacestat after 1 additional year of treatment due to achieving complete remission
 - b. Responses remained durable and the objective response rate (ORR) at the 4-year analysis remained consistent with the primary analysis
 - c. The ORR numerically increased for patients who continued nirogacestat therapy at the 4-year analysis**
- 3. Analyses from the open-label extension of the Phase III DeFi study evaluating nirogacestat versus placebo for patients with progressing desmoid tumors reported which of the following regarding the overall incidence of adverse events?**
 - a. They increased after year 1 of continuous nirogacestat treatment, but were generally manageable
 - b. They remained the same after year 1 of continuous nirogacestat treatment, with no new safety signals
 - c. They remained the same after year 1 of continuous nirogacestat treatment, except for an increased incidence of ovarian toxicity
 - d. They decreased after year 1 of continuous nirogacestat treatment**
- 4. What was the approximate time to response observed with nirogacestat in the Phase III DeFi study?**
 - a. 1 month
 - b. 2.8 months
 - c. 5.6 months**
 - d. 10.2 months
 - e. 18.4 months